AbbVie (ABBV) Net Cash Flow (QoQ) (2012 - 2026)
AbbVie (ABBV) Net Cash Flow (QoQ) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -167.44% |
| Mar 31, 2026 | 1,115.57% |
| Dec 31, 2025 | 50.48% |
| Sep 30, 2025 | -165.77% |
| Jun 30, 2025 | 452.51% |
| Mar 31, 2025 | 78.78% |
| Dec 31, 2024 | 71.31% |
| Sep 30, 2024 | -19.34% |
| Jun 30, 2024 | -193.49% |
| Mar 31, 2024 | 1,162.70% |
| Dec 31, 2023 | -110.92% |
| Sep 30, 2023 | 120.80% |
| Jun 30, 2023 | 182.39% |
| Mar 31, 2023 | 5.88% |
| Dec 31, 2022 | -178.75% |
| Sep 30, 2022 | 37.21% |
| Jun 30, 2022 | 167.20% |
| Mar 31, 2022 | -51.79% |
| Dec 31, 2021 | -165.49% |
| Sep 30, 2021 | 397.49% |